The Company’s headquarter is located at 3675 Market Street, Suite 200, Philadelphia, PA 19104
Carisma is incorporated in the state of Delaware in May 2016.
Carisma is traded on the Nasdaq Stock Market LLC under the ticker symbol “CARM”. On March 7, 2023, the Company completed a merger with Sesen Bio, previously traded under the ticker symbol “SESN”, and the combined company now operates under the name Carisma Therapeutics.
The CUSIP number for Carisma’s common stock is 14216R 101.
Shares can be purchased through a stockbroker of your choice. Carisma does not have a direct stock purchase plan.
Carisma currently intends to retain all available funds to finance the growth and development of our business and does not anticipate paying any dividends on common stock in the foreseeable future.
The Company’s fiscal year ends on December 31st.
Communication regarding transfer requirements, lost certificates, and change of address should be directed to:
Computershare Trust Company, N.A.
P.O. Box 43078
Providence, RI 02940-3078
+1 800-962-4284
Courier Delivery:
Computershare Trust Company, N.A.
150 Royall St., Suite 101
Canton, MA 02021
Investor Centre website
www.computershare.com/investor
Our Legal Counsel is:
WilmerHale
7 World Trade Center
250 Greenwich Street
New York, NY 10007 USA
Our Independent Auditors are:
KPMG LLP
1601 Market Street
Philadelphia, Pennsylvania 19103
Carisma press release archives can be viewed in the Press Releases section of our Investor Relations webpage.
To sign up to receive the latest press releases and other company information, please visit the Investor Relations section and select the "Email Alerts" button to be added to the Carisma distribution list.
Quarterly and annual reports, as well as other SEC filings, can be accessed in the Financial Information section of our Investor Relations webpage or directly from the SEC at www.sec.gov.
For a list of the Executive Management team and Board of Directors please visit the Corporate Governance tab of our website.
You can submit questions to the Carisma investor relations team by contacting Investors@Carismatx.com.